Description: <b>Ascorbyl palmitate</b> is an ester formed from ascorbic acid and palmitic acid creating a fat-soluble form of vitamin C. Ascorbyl palmitate is a highly bioavailable, fat-soluble form of ascorbic acid (vitamin C) and possesses all the properties of native water-soluble counterpart, that is vitamin C.<br>
<p><b>Ascorbyl Palmitate</b> — Ascorbyl palmitate (AP; also called L-ascorbyl palmitate, vitamin C palmitate) is the 6-O-palmitate ester of L-ascorbic acid, used primarily as a lipid-phase antioxidant/preservative (food additive E304(i), INS 304(i)) and in topical/cosmetic formulations. It is an amphipathic, fat-soluble vitamin C derivative that localizes to lipid interfaces and can be enzymatically hydrolyzed to ascorbic acid + palmitate (extent and site depend on formulation and biology). In the Nestronics index (pid 35), AP is linked to limited cancer-pathway annotations largely derived from a small nanoformulation literature rather than broad clinical oncology deployment.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Lipid-phase antioxidant activity (radical scavenging; inhibition of lipid peroxidation at membranes/oil–water interfaces)</li>
<li>Membrane redox modulation with possible pro-oxidant behavior under specific conditions (secondary; model-/matrix-dependent)</li>
<li>IL-6/STAT3 signaling suppression with downstream anti-proliferative and pro-apoptotic effects (preclinical; prominent in AP nanoformulations)</li>
<li>Anti-angiogenic signaling effects reported in tumor models (e.g., VEGF/NO axis; preclinical)</li>
<li>Anti-migration/invasion effects (e.g., MMP-related readouts; preclinical)</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> As a fatty acid ester, AP partitions into dietary and biological lipids; oral exposure is formulation-dependent and it is generally believed to undergo esterase-mediated hydrolysis to ascorbic acid plus palmitate. Human oncology-relevant systemic PK for intact AP is not well standardized in the open literature; most “therapeutic” claims rely on delivery systems (e.g., solid lipid nanoparticles) rather than conventional oral supplement dosing.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many mechanistic cancer studies use micromolar-to-millimolar in-vitro concentrations and/or nano-enabled delivery that can exceed typical systemic levels achievable from food-additive exposure; translation hinges on formulation, local delivery, and tumor targeting rather than simple oral dosing.</p>
<p><b>Clinical evidence status:</b> Predominantly preclinical (in vitro/in vivo) and largely formulation-driven (nano/SLN platforms). No established role as an anticancer drug in routine clinical oncology; clinical use is mainly as an antioxidant excipient/food additive.</p>
<h3>Ascorbyl Palmitate — Mechanistic Pathway Matrix (Cancer Context)</h3>
<table>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
<tr>
<td>1</td>
<td>Lipid peroxidation control</td>
<td>↓ lipid peroxidation (context-dependent)</td>
<td>↓ lipid peroxidation</td>
<td>P</td>
<td>Antioxidant stabilization of lipid phases</td>
<td>Core identity is a lipid-phase antioxidant used to protect fats/oils and membranes; mechanistic centrality is redox buffering rather than direct oncogene targeting.</td>
</tr>
<tr>
<td>2</td>
<td>ROS balance</td>
<td>↔ (model-dependent; can be pro-oxidant at high concentration or in specific matrices)</td>
<td>↔ (model-dependent)</td>
<td>P</td>
<td>Redox modulation</td>
<td>Some datasets (including food-matrix and additive evaluations) note condition-dependent pro-oxidant behavior; interpret as context- and co-antioxidant–dependent rather than a fixed direction.</td>
</tr>
<tr>
<td>3</td>
<td>IL-6 / STAT3 axis</td>
<td>↓ (preclinical; strongest in nanoformulations)</td>
<td>Unknown / not established</td>
<td>R</td>
<td>Anti-proliferative signaling shift</td>
<td>STAT3↓ and IL6↓; primary open literature support clusters around AP nanoformulations reporting STAT3 pathway inhibition with tumor growth suppression.</td>
</tr>
<tr>
<td>4</td>
<td>Apoptosis</td>
<td>↑ (preclinical; formulation-dependent)</td>
<td>↔ / safety generally favorable at permitted exposures</td>
<td>R</td>
<td>Programmed cell death induction</td>
<td>Often downstream of stress + signaling changes (e.g., STAT3 suppression) in tumor models; not a validated clinical anticancer mechanism for standard oral exposure.</td>
</tr>
<tr>
<td>5</td>
<td>Cell cycle regulation</td>
<td>↓ proliferation / cell-cycle arrest (model-dependent)</td>
<td>↔</td>
<td>G</td>
<td>Growth suppression</td>
<td>Reported G2/M arrest appears in AP nanoparticle studies; treat as secondary to upstream stress/signaling.</td>
</tr>
<tr>
<td>6</td>
<td>Angiogenesis / NO signaling</td>
<td>↓ VEGF / ↓ NO (preclinical)</td>
<td>↔ (context-dependent)</td>
<td>G</td>
<td>Anti-angiogenic phenotype</td>
<td>VEGF↓/NO↓/angioG↓; evidence is not broad across tumor types and appears tied to specific experimental systems.</td>
</tr>
<tr>
<td>7</td>
<td>Migration / invasion</td>
<td>↓ MMP-related invasion signals (preclinical)</td>
<td>↔</td>
<td>G</td>
<td>Reduced metastatic traits</td>
<td>MMP9↓ and TumMeta↓; mechanistic specificity remains limited outside a small formulation-driven literature.</td>
</tr>
<tr>
<td>8</td>
<td>NRF2 axis</td>
<td>↔ (not clearly established as a primary AP mechanism)</td>
<td>↔</td>
<td>G</td>
<td>Secondary antioxidant-response tuning</td>
<td>Unlike many electrophilic polyphenols, AP’s primary chemistry is radical scavenging in lipid phases; NRF2 involvement (if present) is typically indirect and context-driven.</td>
</tr>
<tr>
<td>9</td>
<td>Clinical Translation Constraint</td>
<td>Formulation-driven exposure requirement</td>
<td>Food-additive exposures are low</td>
<td>—</td>
<td>Limits on oncology leverage</td>
<td>Regulatory acceptance is for antioxidant use (GMP/food additive contexts), but oncology-relevant effects mostly rely on nano/targeted delivery; intact-AP systemic PK and tumor delivery are the main bottlenecks.</td>
</tr>
</table>
<p><b>TSF legend:</b> P: 0–30 min R: 30 min–3 hr G: >3 hr</p>